This year it will be 30 years ago that Cardiovascular Drugs and Therapy, commonly known by its abbreviated title CDT, was founded by Henry Neufeld and Lionel Opie. Whereas, unfortunately, Henry Neufeld died before the first issue was published, Lionel Opie continued as Editor-in-Chief for the first 15 years of the Journal's existence, and made the journal to flourish together with Elliot Rapaport who served as CoEditor-in-Chief from 1988 to 1998
In 2001 I followed up Lionel Opie as the Journal's Editor-inChief and have been in this fortunate position since that time.
Fortunate as CDT has steadily improved during those years and has obtained citation indices of more than 3 in the last 5 years. The journal is currently well known as indicated by the large yearly number of downloads of up to 60.000. An important aspect of CDT is its fast handling of the manuscripts (for example an average of 19 days from receipt to first decision and 19 days between acceptance and on-line publication [2015 figures] ). This achievement is to a large extent the result of the excellent support and hard work of an experienced team of Associate and Section Editors and of members of the Editorial Board.
CDT is designed to cover the bench to bedside development of cardiovascular drug, device and cell therapy and to provide an up-to-date account of relevant research in a broad spectrum of cardiovascular diseases including cardiotoxicity, ischaemic syndromes, cardioprotection, atherosclerosis, hyperlipidemia, diabetes and arrhythmias.
This approach is, by design, extensive and can be very demanding for a sole Editor-in-Chief, certainly when the ultimate goal is to keep improving the standard of the Journal and to achieve a continuously increasing citation index.
I am therefore very happy to be able to announce that Dr. Dr. Rosenson has been involved in numerous research investigations studying the effects of lipid-lowering therapy, hypoglycemic therapy, and antihypertensive agents in inflammation, thrombogenesis, and rheology. His laboratory was the first to demonstrate that statins reduce pro-inflammatory cytokine production. He has continued this work through mechanistic studies on inflammatory markers with studies on fenofibrate. Most recently, he has conducted research with selective inhibitors of inflammatory pathways such as lipoprotein-associated phospholipase A2, and secretory phospholipase A2. He has made important contributions concerning the prognostic significance of lipoprotein subclasses in coronary atherosclerosis, cardiovascular events and prediction of type 2 diabetes. He served as Global Principal Investigator of the PLASMA I, PLASMA II and FRANCIS trials. He has authored more than 260 peerreview journal articles, and 700 book chapters, abstracts, and electronic publications for Up To Date Medicine.
Dr [1] [2] [3] [4] [5] [6] [7] . Moreover, as Associate Editor Dr. Rosenson advised on the choice of reviewers and on acceptance or rejects of submissions to the Journal.
I am convinced that with this experience and his expert knowledge of a broad area of cardiovascular diseases, including atherosclerosis, hyperlipidemia, diabetes and hypertension, Dr. Rosenson is in a unique position to serve as CoEditor-in-Chief of Cardiovascular Drugs and Therapy.
I am delighted therefore that he has accepted his new function and look forward to working with him as Co-Editor-inChief
